ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions

Bourdin, Arnaud; Bjermer, Leif; Brightling, Christopher E.; Brusselle, Guy; Chanez, Pascal; Chung, Kian Fan; Čustović, Adnan; Diamant, Zuzana; Diver, Sarah; Djukanović, Ratko; Hamerlijnck, Dominique; Horváth, Ildikó; Johnston, Sebastian L.; Kanniess, Frank; Papadopoulos, Nikos; Papi, Alberto; Russell, Richard J.; Ryan, Dermot; Samitas, Κonstantinos; Tonia, Thomy; Ζervas, Εleftherios; Gaga, Mina

doi:10.1183/13993003.00900-2019

Cited by 61 publications

(39 citation statements)

References 224 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevention of exacerbations remains an important therapeutic target for patients with asthma [23]. In this study, we observed an 86.2% reduction from baseline in exacerbation rate after both 12 and 24 months of follow-up.…”

Section: Discussionsupporting

confidence: 52%

Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme

et al. 2020

Self Cite

View full text Add to dashboard Cite

BackgroundMepolizumab was available in France as part of an early access programme for patients with severe eosinophilic asthma (nominative autorisation temporaire d'utilisation [temporary use authorisation] (nATU)) before its commercialisation. This study aimed to characterise patients who received mepolizumab in the nATU.MethodsThis retrospective, observational study analysed data from the hospital medical records of patients up to 24 months after treatment initiation. Study objectives were to describe patient baseline characteristics, the evolution of disease severity and treatment modifications during follow-up; safety was also investigated.FindingsOverall, 146 patients who received ≥1 dose of mepolizumab were included. At inclusion, patients had a mean age of 58.2 years with a mean severe asthma duration of 13.4 years, and 37.0% had respiratory allergies. Patients experienced, on average, 5.8 exacerbations per patient per year at baseline, 0.6 and 0.5 of which required hospitalisation and emergency department visits, respectively. These values improved to 0.6, 0.1 and 0.1 exacerbations per patient per year, respectively, at 24 months of follow-up. Most patients (92.8%) were using oral corticosteroids at baseline, compared with 34.7% by 24 months of follow-up. Moreover, mean blood eosinophil counts improved from 722 cells·µL−1 at baseline to 92 cells·µL−1 at 24 months of follow-up; lung function and asthma control followed a similar trend.InterpretationResults confirm findings from clinical trials, demonstrating that mepolizumab is associated with important improvements in several clinically meaningful outcomes and has a favourable safety profile in a population with severe eosinophilic asthma, outside of the controlled environment of a clinical trial.

show abstract

Section: Discussionsupporting

confidence: 52%

Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…To date, there is very little information available on patients with asthma who have COVID‐19. In general, viruses, including rhinoviruses and respiratory syncytial viruses, have been shown to induce asthma episodes or exacerbations 118,119 . Mounting evidence implicates that particular viral pathogens, namely the human rhinovirus and respiratory syncytial virus, are among the most likely culprits in asthma inception 119 .…”

Section: Specific Considerations In the Management Of Different Allermentioning

confidence: 99%

“…In general, viruses, including rhinoviruses and respiratory syncytial viruses, have been shown to induce asthma episodes or exacerbations. 118,119 Mounting evidence implicates that particular viral pathogens, namely the human rhinovirus and respiratory syncytial virus, are among the most likely culprits in asthma inception. 119 Bacterial infections and colonization have also been associated with exacerbation and recurrent wheeze, an effect that may be independent, or a cofactor with viruses.…”

Section: Asthmamentioning

confidence: 99%

COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Pfaar

Klimek

Jutel

et al. 2021

Allergy

Self Cite

152

View full text Add to dashboard Cite

Background The coronavirus disease 2019 (COVID‐19) has evolved into a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS‐CoV‐2). Allergists and other healthcare providers (HCPs) in the field of allergies and associated airway diseases are on the front line, taking care of patients potentially infected with SARS‐CoV‐2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics. Method The scientific information on COVID‐19 was analysed by a literature search in MEDLINE, PubMed, the National and International Guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library, and the internet. Results Based on the diagnostic and treatment standards developed by EAACI, on international information regarding COVID‐19, on guidelines of the World Health Organization (WHO) and other international organizations, and on previous experience, a panel of experts including clinicians, psychologists, IT experts, and basic scientists along with EAACI and the “Allergic Rhinitis and its Impact on Asthma (ARIA)” initiative have developed recommendations for the optimal management of allergy clinics during the current COVID‐19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies. Conclusions This international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients while ensuring the necessary safety measures in the current COVID‐19 pandemic.

show abstract

“…Among patients who end up at the ICU, the mortality rate is high [ 1 ]. While individuals with chronic respiratory diseases such as allergy, asthma and COPD are generally at risk of virally induced (severe) exacerbations [ 2 ], interestingly, these populations seemed under-represented among those with severe-COVID-19 disease in the initial reports from China [ 3 , 4 ]. However, more recent reports from the USA COVID-NET hospitals show chronic lung disease as an underlying condition in approximately 30% of hospitalized patients with COVID-19 [ 5 ], while especially those with COPD appeared at risk [ 6 ].…”

mentioning

confidence: 99%

Clinical and daily respiratory care and clinical trials within the COVID-19 era

Diamant

Bjermer

Backer

2020

European Clinical Respiratory Journal

Self Cite

View full text Add to dashboard Cite

show abstract

ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions

Cited by 61 publications

References 224 publications

Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme

Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme

COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Clinical and daily respiratory care and clinical trials within the COVID-19 era

Contact Info

Product

Resources

About